COVID-19 Drives Adoption of Shorter Breast Radiation Therapy

The COVID‑19 pandemic has accelerated the shift toward shorter‑course radiation therapy for women with early‑stage breast cancer, a finding reported in a new study in the *American Journal of Clinical Oncology*. The research shows that the compressed treatment schedules, which reduce the number of hospital visits, have become more widely adopted during the pandemic and have led to a measurable decrease in both patient burden and overall health‑care costs.

The study analyzed data from multiple oncology centers and compared outcomes and expenditures for patients receiving conventional multi‑week regimens versus abbreviated protocols. Results indicated that the abbreviated schedules maintained comparable clinical efficacy while significantly lowering the financial impact on patients and payers. The authors note that the pandemic’s restrictions on in‑person care prompted rapid adoption of these regimens, which may now become a standard of care even after the acute phase of the crisis.

In conclusion, the accelerated uptake of shorter‑course radiation therapy during COVID‑19 has demonstrated that more efficient treatment schedules can be both clinically effective and economically advantageous, potentially reshaping standard practices for early‑stage breast cancer care.